CN113101412A - Long-acting stable anticoagulation biological valve material and preparation method thereof - Google Patents
Long-acting stable anticoagulation biological valve material and preparation method thereof Download PDFInfo
- Publication number
- CN113101412A CN113101412A CN202110229808.7A CN202110229808A CN113101412A CN 113101412 A CN113101412 A CN 113101412A CN 202110229808 A CN202110229808 A CN 202110229808A CN 113101412 A CN113101412 A CN 113101412A
- Authority
- CN
- China
- Prior art keywords
- biological valve
- dopamine
- long
- valve material
- zwitterionic polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/38—Esters containing sulfur
- C08F220/387—Esters containing sulfur and containing nitrogen and oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F230/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
Abstract
The invention discloses a long-acting stable anticoagulation biological valve material and a preparation method thereof, belonging to the technical field of biological valve material preparation. The biological valve material prepared by the invention is a glutaraldehyde cross-linked biological valve material, and the polymer and the glutaraldehyde are cooperated to cross-link the biological valve material, so that the problems of short anticoagulation effective time and poor stability in the existing artificial biological valve can be solved, and the biological valve material has good biocompatibility and anticoagulation performance.
Description
Technical Field
The invention relates to the technical field of preparation of biological valve materials, in particular to a long-acting stable anticoagulation biological valve material and a preparation method thereof.
Background
In recent years, the incidence and mortality of global cardiovascular and cerebrovascular diseases are high, wherein the valvular heart disease is seriously threatened to the life health of residents. Surgical open chest replacement valve surgery and transcatheter minimally invasive valve replacement surgery are common treatment modalities for heart valve disease. However, whether the diseased valve is replaced by surgery or minimally invasive intervention, the patient needs to receive anticoagulant medication to reduce the incidence of adverse events. Mechanical valves are commonly used in surgical operations, and patients need to take anticoagulant drugs for life. In recent years, minimally invasive interventional surgery is gradually the first choice for valve replacement due to the advantages of small trauma, fast recovery and the like. However, the biological valve subjected to minimally invasive catheterization through a catheter also has the problem of thrombus, and how to endow the artificial biological valve with excellent anticoagulation performance becomes the key and difficult point for developing a new generation of artificial biological valve.
Heparin or hydrophilic compounds are often added during the preparation of the bioprosthetic valve to impart anticoagulation to the bioprosthetic valve. However, the fixation of these functional molecules to the biological valve by non-chemical bonding is often effective for a short time, and the biological valve still faces the risk of thrombus. In addition, modification of heparin onto a biological valve by covalent bonds severely reduces the anticoagulation effect of heparin, making it difficult to obtain a biological valve with excellent anticoagulation performance. In addition, the crosslinked artificial biological valve is further subjected to surface modification treatment, and the preparation of an anticoagulation coating on the surface of the biological valve is also an effective method for preparing the artificial biological valve with the anticoagulation function, but the surface modification also has the problems of poor coating stability, short validity period, possibility of reducing the mechanical property of the artificial biological valve and the like.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a long-acting stable anticoagulation biological valve material and a preparation method thereof, and aims to solve the problems of short anticoagulation effective time and poor stability in the existing artificial biological valve.
In order to achieve the purpose, the technical scheme adopted by the invention for solving the technical problems is as follows:
the invention provides a long-acting stable anticoagulation biological valve material and a preparation method thereof, and the process comprises the following steps: modifying a biological valve by using a dopamine zwitterionic polymer, and then performing glutaraldehyde crosslinking treatment;
or crosslinking the biological valve by using glutaraldehyde, and then modifying the dopamine zwitterionic polymer;
or modifying the biological valve by using the dopamine zwitterionic polymer, then performing glutaraldehyde crosslinking treatment, and finally further treating the biological valve by using the dopamine zwitterionic polymer;
the dopamine zwitterionic polymer is a polymer A or a polymer B, x is 10-400, y is 10-500, and the specific chemical structural formula is as follows:
further, the specific process of modification treatment of the biological valve by the dopamine zwitterionic polymer is as follows: the biological valve or the biological valve after the glutaraldehyde crosslinking treatment is soaked in dopamine zwitterionic polymer aqueous solution with the mass concentration of 1 mg/mL-500 mg/mL and reacts for 6-72 hours at the temperature of 4-37 ℃ and under the condition of the pH value of 2.0-8.0.
Further, the specific process of the glutaraldehyde crosslinking treatment on the biological valve is as follows: placing the biological valve in a glutaraldehyde solution with the mass concentration of 0.05-8%, and crosslinking for 1-5 days at the temperature of 4-37 ℃ and the pH value of 2.0-9.0.
Further, when the dopamine zwitterionic polymer is used for modifying a biological valve, the concentration of the dopamine zwitterionic polymer is preferably 40mg/mL, the reaction time is preferably 24 hours, and the reaction temperature is preferably 20 ℃.
Further, when the dopamine zwitterionic polymer is added in the glutaraldehyde crosslinking process, the biological valve is firstly soaked in the dopamine zwitterionic polymer for 1-24 hours, and the preferable time is 4 hours.
Further, when glutaraldehyde is used for the biological valve cross-linking treatment, the mass concentration of glutaraldehyde is preferably 0.8%.
Further, the biological valve material is porcine pericardium or bovine pericardium.
Further, after the dopamine zwitterionic polymer is bonded on the biological valve, the biological valve is further treated by one or more of aminoglycerol, glucosamine, lysine, arginine, mannosamine, glucosamine or galactosamine with the mass concentration of 2% -10%, and the treatment time is 20-30 hours.
Further, the preparation method of the dopamine zwitterionic polymer comprises the following steps:
adding 2-methacryloyloxyethyl phosphorylcholine (formula II) or 3- [ N, N-dimethyl- [2- (2-methylpropane-2-enoyloxy) ethyl ] ammonium ] propane-1-sulfonic acid inner salt (formula III), methacrylic acid dopamine ester (formula I), a free radical initiator and a chain transfer reagent in a molar ratio of 1: 1-2: 0.005-0.015: 0.02-0.04 into a reaction vessel, adding a solvent, reacting for 20-30 hours at 65-80 ℃ under the protection of argon, concentrating the reaction solution after the reaction is finished, dropwise adding the concentrated reaction solution into anhydrous ether, collecting precipitates, and drying at 20-50 ℃ in vacuum to prepare the dopamine amphoteric Ionomer (IV) or the dopamine amphoteric ionomer (V).
Further, a solvent used in the preparation process of the dopamine zwitterionic polymer is one or more of toluene, methanol, ethanol, tetrahydrofuran, dimethyl sulfoxide, water, N-dimethylformamide and dioxane, and the concentration of the solvent is 0.1M; the free radical initiator is azobisisobutyronitrile, azobisisoheptonitrile, acetyl peroxide or benzoyl peroxide; the chain transfer agent is 4-cyano-4- (phenylthioformylthio) pentanoic acid, benzyl dithiobenzoate or isopropylphenyl dithiobenzoate.
Further, the reaction temperature during the preparation of the dopamine zwitterionic polymer is preferably 70 ℃, the reaction time is preferably 24 hours, and the vacuum drying temperature is preferably 40 ℃.
The long-acting stable anticoagulation biological valve material prepared by the method.
In summary, the invention has the following advantages:
1. the polymer is fixed on the valve body and the surface in a chemical bonding mode, so that the mechanical property of the biological valve cannot be reduced, and compared with the biological valve modified through electrostatic action or physical filling action, the biological valve modified by the polymer has longer acting and more stable anticoagulation capacity, and is beneficial to prolonging the service life of the biological valve;
2. the biological valve modification method provided by the invention can effectively reduce residual aldehyde groups on the biological valve and reduce the problems of calcification and biological toxicity of the biological valve;
3. according to the invention, a large number of hydrophilic groups are introduced into the body and the surface of the biological valve, so that a stable hydration layer can be formed on the surface of the biological valve, platelet adhesion is effectively reduced, and the blood coagulation risk is reduced.
Drawings
Fig. 1 is a scanning electron microscope image of the adhesion experiment of the biological valve material and the blood platelets of example 1 and comparative example 1 of the invention.
Detailed Description
Example 1
The embodiment 1 provides a preparation method of a long-acting stable anticoagulation biological valve material, which specifically comprises the following steps:
(1) enveloping fresh pig hearts, removing connective tissues, cleaning, and further washing with normal saline;
(2) soaking the pig heart envelope obtained in the step (1) in a polymer aqueous solution with the mass concentration of 30mg/mL, reacting for 10 hours at the temperature of 20 ℃ and under the condition that the pH value is 8.0, taking out and cleaning;
(3) soaking the pig heart envelope in the step (2) in a glutaraldehyde solution with the mass concentration of 1%, performing crosslinking treatment for 24 hours at the temperature of 25 ℃ and under the condition that the pH value is 7.0, taking out, and cleaning with distilled water;
(4) further soaking the pig heart capsule with arginine with the mass concentration of 2% for 24 hours, and then taking out and cleaning with distilled water.
The preparation process of the dopamine zwitterionic polymer is as follows:
2-methacryloyloxyethylphosphonic acid choline (4.00g,13.56mmol), dopamine methacrylate (3.65g,16.01mmol), azobisisobutyronitrile (28.18mg,0.17mmol), 4-cyano-4- (phenylthiocarbonylthio) pentanoic acid (120.27mg,0.43mmol), 10mL of methanol and 10mL of tetrahydrofuran were added to a thick-walled pressure bottle, and oxygen was removed by introducing argon gas into the solution and evacuating, and the reaction was carried out at 70 ℃ for 24 hours under the protection of argon gas. After the reaction, the liquid was concentrated, precipitated with ether, and dried under vacuum to obtain 6.9g of dopamine zwitterionic polymer with a yield of 90.20%.
Example 2
The embodiment 2 provides a preparation method of a long-acting stable anticoagulation biological valve material, which specifically comprises the following steps:
(1) enveloping fresh pig hearts, removing connective tissues, cleaning, and further washing with normal saline;
(2) soaking the pig heart envelope obtained in the step (1) in a polymer aqueous solution with the mass concentration of 500mg/mL, taking out the pig heart envelope and cleaning the pig heart envelope after 10 hours at the temperature of 4 ℃ and the pH value of 2.0;
(3) soaking the pig heart envelope in the step (2) in a glutaraldehyde solution with the mass concentration of 8%, performing crosslinking treatment for 48 hours at the temperature of 25 ℃ and under the condition of pH 8.0, taking out, and cleaning with distilled water;
(4) further soaking the pig heart envelope with 5% of amino glycerol for 24 hours, and then taking out and cleaning with distilled water.
The preparation process of the dopamine zwitterionic polymer is as follows:
2-methacryloyloxyethyl phosphorylcholine (5.00g,16.95mmol), dopamine methacrylate (4.56g,20.01mmol) and azobisisobutyronitrile (72mg,0.44mmol) were dissolved in 15mL of N, N-dimethylformamide, added to a reaction flask, and reacted under argon protection at 70 ℃ for 24 hours after three freeze-pump-thaw cycles. After the reaction, the liquid was concentrated, precipitated with ether, and dried under vacuum to obtain 8.13g of dopamine zwitterionic polymer with a yield of 85.00%.
Example 3
The embodiment 3 provides a preparation method of a long-acting stable anticoagulation biological valve material, which specifically comprises the following steps:
(1) enveloping fresh pig hearts, removing connective tissues, cleaning, and further washing with distilled water;
(2) soaking the pig heart envelope membrane in the step (1) in a polymer water solution with the mass concentration of 1mg/mL, adding a glutaraldehyde solution under the conditions of 20 ℃ and pH of 8.0 for 6 hours, continuing crosslinking treatment at 25 ℃ for 24 hours, taking out, and cleaning with distilled water;
(3) further soaking the pig heart capsule with 3% arginine for 24 hr, and cleaning with distilled water.
The dopamine zwitterionic polymer described above is the same as in example 1.
Example 4
The embodiment 4 provides a preparation method of a long-acting stable anticoagulation biological valve material, which specifically comprises the following steps:
(1) enveloping fresh pig hearts, removing connective tissues, cleaning, and further washing with distilled water;
(2) soaking the pig heart envelope obtained in the step 1 in a glutaraldehyde solution with the mass concentration of 5%, performing crosslinking treatment for 24 hours at the temperature of 25 ℃ and under the condition that the pH value is 5.0, and then taking out and cleaning the pig heart envelope by using distilled water;
(3) soaking the glutaraldehyde cross-linked pig heart envelope in a polymer aqueous solution with the mass concentration of 200mg/mL for 24 hours, taking out and cleaning;
(4) further soaking the pig heart capsule with 2.5% of arginine and 3% of amino glycerol for 24 hours, and then taking out and cleaning with distilled water.
The dopamine zwitterionic polymer described above is the same as in example 1.
Example 5
The embodiment 5 provides a preparation method of a long-acting stable anticoagulation biological valve material, which specifically comprises the following steps:
(1) enveloping fresh pig hearts, removing connective tissues, cleaning, and further washing with distilled water;
(2) soaking the pig heart envelope obtained in the step (1) in a polymer aqueous solution with the mass concentration of 25mg/mL, reacting for 24 hours at 37 ℃ under the condition of pH 8.0, taking out and cleaning;
(3) soaking the pig heart envelope in the step (2) in a glutaraldehyde solution with the mass concentration of 5%, performing crosslinking treatment for 24 hours at the temperature of 25 ℃ and under the condition of pH 7.0, taking out, and cleaning with distilled water;
(4) further soaking the pericardium in the step (3) in a polymer water solution with the mass concentration of 20mg/mL for 24 hours;
(5) further soaking the pig heart capsule with 2% of arginine and 3% of amino glycerol for 24 hours, and then taking out and cleaning with distilled water.
The dopamine zwitterionic polymer described above is the same as in example 1.
Example 6
The embodiment 6 provides a preparation method of a long-acting stable anticoagulation biological valve material, which specifically comprises the following steps:
(1) enveloping fresh pig hearts, removing connective tissues, cleaning, and further washing with distilled water;
(2) soaking the pig heart envelope obtained in the step (1) in a polymer aqueous solution with the mass concentration of 30mg/mL, taking out the pig heart envelope and cleaning the pig heart envelope with distilled water after 10 hours at the temperature of 4 ℃ and the pH value of 8.0;
(3) soaking the pig heart envelope in the step (2) in a glutaraldehyde solution with the mass concentration of 1%, performing crosslinking treatment for 24 hours at the temperature of 25 ℃ and under the condition of pH 7.0, taking out, and cleaning with distilled water;
(4) further soaking the pericardium in the step (3) in a polymer water solution with the mass concentration of 20mg/mL for 24 hours;
(5) further soaking the pig heart capsule with 2% of arginine and 3% of amino glycerol for 24 hours, and then taking out and cleaning with distilled water.
The dopamine zwitterionic polymer described above is the same as in example 1.
Comparative example 1
The comparative example 1 provides a preparation method of a glutaraldehyde cross-linked biological valve material, which specifically comprises the following steps: enveloping fresh pig hearts, removing connective tissues, cleaning, further washing with distilled water, adding a glutaraldehyde solution with the final mass concentration of 1% of glutaraldehyde, continuing to soak for 24 hours, and then taking out and washing with distilled water.
Experimental example 1
In order to examine the performance of the zwitterionic polymer modified biological valve material prepared by the invention, the biological membrane material obtained in the example 1 and the biological membrane material crosslinked by glutaraldehyde obtained in the comparative example 1 are cut into the size of 1 × 5cm, incubated with platelet-rich plasma for 1 hour at 37 ℃, then fixed by paraformaldehyde, dried and observed by a scanning electron microscope to observe the adhesion condition of platelets on the surface of the biological membrane material, and the test result is shown in fig. 1; wherein, the left side (A) in FIG. 1 is the test result of the biofilm material obtained in example 1, and the right side (B) in FIG. 1 is the test result of the glutaraldehyde-crosslinked biofilm material obtained in comparative example 1.
As can be seen from fig. 1, platelets adhered to the surface of the bio-valve material modified by the zwitterionic polymer prepared in example 4 of the present invention are significantly less than the glutaraldehyde-crosslinked bio-valve material prepared in comparative example 1, and the surface zwitterionic polymer modification can effectively improve the anticoagulation performance of the bio-valve material, and can effectively solve the problems of short anticoagulation effective time and poor stability existing in the existing artificial bio-valve.
The foregoing is illustrative and explanatory only and is not intended to be exhaustive or to supplement or replace the specific embodiments described by those skilled in the art without inventive faculty.
Claims (9)
1. A preparation method of a long-acting stable anticoagulation biological valve material is characterized in that a dopamine zwitterionic polymer is used for modifying a biological valve, and then glutaraldehyde crosslinking treatment is carried out;
or crosslinking the biological valve by using glutaraldehyde, and then modifying the dopamine zwitterionic polymer;
or modifying the biological valve by using the dopamine zwitterionic polymer, then performing glutaraldehyde crosslinking treatment, and finally further treating the biological valve by using the dopamine zwitterionic polymer;
the dopamine zwitterionic polymer is a polymer A or a polymer B, x is 10-400, y is 10-500, and the specific chemical structural formula is as follows:
2. the method for preparing a long-acting stable anticoagulation biological valve material according to claim 1, wherein the modification treatment process of the dopamine zwitterionic polymer on the biological valve comprises the following steps: the biological valve or the biological valve after the glutaraldehyde crosslinking treatment is soaked in dopamine zwitterionic polymer aqueous solution with the mass concentration of 1 mg/mL-500 mg/mL and reacts for 6-72 hours at the temperature of 4-37 ℃ and under the condition of the pH value of 2.0-8.0.
3. The method for preparing a long-acting stable anticoagulation biological valve material according to claim 2, wherein the concentration of the dopamine zwitterionic polymer is 40mg/mL, the reaction time is 24 hours, and the reaction temperature is 20 ℃.
4. The method for preparing the long-acting stable anticoagulation biological valve material according to claim 1, wherein the glutaraldehyde crosslinking treatment process for the biological valve is as follows: placing the biological valve in a glutaraldehyde solution with the mass concentration of 0.05-8%, and crosslinking for 1-5 days at the temperature of 4-37 ℃ and the pH value of 2.0-9.0.
5. The method for preparing a long-acting stable anticoagulation biological valve material according to claim 4, wherein the mass concentration of glutaraldehyde is 0.8%.
6. The method of preparing a long-acting stable anticoagulation biological valve material according to claim 1, wherein the biological valve material is porcine pericardium or bovine pericardium.
7. The method for preparing a long-acting stable anticoagulation biological valve material according to claim 1, wherein the method for preparing dopamine zwitterionic polymer comprises the following steps:
adding 2-methacryloyloxyethyl phosphorylcholine (formula II) or 3- [ N, N-dimethyl- [2- (2-methylpropane-2-enoyloxy) ethyl ] ammonium ] propane-1-sulfonic acid inner salt (formula III), dopamine methacrylate (formula I), a free radical initiator and a chain transfer reagent into a reaction vessel according to a molar ratio of 1: 1-2: 0.005-0.015: 0.02-0.04, adding a solvent, and reacting at 65-80 ℃ for 20-30 hours under the protection of argon to prepare the dopamine amphoteric ion polymer (IV) or the dopamine amphoteric ion polymer (V).
8. The method for preparing the long-acting stable anticoagulation biological valve material according to claim 7, wherein the solvent used in the preparation of the dopamine zwitterionic polymer is one or more of toluene, methanol, ethanol, tetrahydrofuran, dimethyl sulfoxide, water, N-dimethylformamide and dioxane; the free radical initiator is azobisisobutyronitrile, azobisisoheptonitrile, acetyl peroxide or benzoyl peroxide; the chain transfer reagent is 4-cyano-4- (phenylthiocarbonylthio) pentanoic acid, benzyl dithiobenzoate or isopropylphenyl dithiobenzoate.
9. A long-acting stable anticoagulation biological valve material prepared by the method of any one of claims 1-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110229808.7A CN113101412A (en) | 2021-03-02 | 2021-03-02 | Long-acting stable anticoagulation biological valve material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110229808.7A CN113101412A (en) | 2021-03-02 | 2021-03-02 | Long-acting stable anticoagulation biological valve material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113101412A true CN113101412A (en) | 2021-07-13 |
Family
ID=76709644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110229808.7A Pending CN113101412A (en) | 2021-03-02 | 2021-03-02 | Long-acting stable anticoagulation biological valve material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113101412A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113769169A (en) * | 2021-10-22 | 2021-12-10 | 四川大学华西医院 | Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof |
| CN114081674A (en) * | 2021-09-28 | 2022-02-25 | 四川大学华西医院 | Valve leaflet segmenting device |
| CN114984332A (en) * | 2022-05-27 | 2022-09-02 | 山东大学 | Dopamine-heparin composite anticoagulant coating and preparation method thereof |
| WO2023088330A1 (en) * | 2021-11-17 | 2023-05-25 | 四川大学 | Biological valve material, and preparation method therefor and use thereof |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270526B1 (en) * | 1993-11-01 | 2001-08-07 | 3F Therapeutics, Inc. | Replacement semilunar heart valves using flexible tubes |
| CN103588933A (en) * | 2013-10-10 | 2014-02-19 | 西北大学 | Multi-bionic anti-biological pollution copolymer, and preparation method and application thereof |
| CN104194023A (en) * | 2014-08-12 | 2014-12-10 | 东南大学 | Dopamine-based method for improving surface hydrophilicity and biocompatibility of medical polyurethane material |
| WO2016040489A1 (en) * | 2014-09-09 | 2016-03-17 | Shaoyi Jiang | Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methds for their use |
| CN107312122A (en) * | 2017-06-02 | 2017-11-03 | 华东理工大学 | Poly-dopamine Methacrylamide sulfobetaines and preparation method and application |
| CN107617126A (en) * | 2017-08-11 | 2018-01-23 | 天津大学 | A kind of surface modification method of porous material and application |
| CN108815552A (en) * | 2018-07-05 | 2018-11-16 | 四川大学 | A kind of drug controllably loads and the bio-medical coating material of long-acting slow-release and preparation method thereof |
| CN108929412A (en) * | 2018-07-10 | 2018-12-04 | 南昌大学 | A kind of preparation method of the adhesiveness injection aquagel of temperature-responsive |
| CN109833519A (en) * | 2018-10-19 | 2019-06-04 | 四川大学 | A kind of method of bioprosthesis valve |
| CN111420120A (en) * | 2020-05-28 | 2020-07-17 | 四川大学 | Biological valve with anticoagulation and anti-calcification functions and preparation method thereof |
| CN111701077A (en) * | 2020-06-24 | 2020-09-25 | 四川大学 | Valve with antithrombotic and anticalcification functions and preparation method and application thereof |
| CN112220971A (en) * | 2020-07-20 | 2021-01-15 | 四川大学 | Artificial biological heart valve and preparation method thereof |
| CN112316218A (en) * | 2020-10-26 | 2021-02-05 | 西北大学 | Zwitterionic polymer and heparin composite coating, preparation method and application thereof |
| CN112375191A (en) * | 2020-10-30 | 2021-02-19 | 清华大学 | Block copolymer, preparation method and application thereof |
-
2021
- 2021-03-02 CN CN202110229808.7A patent/CN113101412A/en active Pending
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270526B1 (en) * | 1993-11-01 | 2001-08-07 | 3F Therapeutics, Inc. | Replacement semilunar heart valves using flexible tubes |
| CN103588933A (en) * | 2013-10-10 | 2014-02-19 | 西北大学 | Multi-bionic anti-biological pollution copolymer, and preparation method and application thereof |
| CN104194023A (en) * | 2014-08-12 | 2014-12-10 | 东南大学 | Dopamine-based method for improving surface hydrophilicity and biocompatibility of medical polyurethane material |
| WO2016040489A1 (en) * | 2014-09-09 | 2016-03-17 | Shaoyi Jiang | Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methds for their use |
| CN107312122A (en) * | 2017-06-02 | 2017-11-03 | 华东理工大学 | Poly-dopamine Methacrylamide sulfobetaines and preparation method and application |
| CN107617126A (en) * | 2017-08-11 | 2018-01-23 | 天津大学 | A kind of surface modification method of porous material and application |
| CN108815552A (en) * | 2018-07-05 | 2018-11-16 | 四川大学 | A kind of drug controllably loads and the bio-medical coating material of long-acting slow-release and preparation method thereof |
| CN108929412A (en) * | 2018-07-10 | 2018-12-04 | 南昌大学 | A kind of preparation method of the adhesiveness injection aquagel of temperature-responsive |
| CN109833519A (en) * | 2018-10-19 | 2019-06-04 | 四川大学 | A kind of method of bioprosthesis valve |
| CN111420120A (en) * | 2020-05-28 | 2020-07-17 | 四川大学 | Biological valve with anticoagulation and anti-calcification functions and preparation method thereof |
| CN111701077A (en) * | 2020-06-24 | 2020-09-25 | 四川大学 | Valve with antithrombotic and anticalcification functions and preparation method and application thereof |
| CN112220971A (en) * | 2020-07-20 | 2021-01-15 | 四川大学 | Artificial biological heart valve and preparation method thereof |
| CN112316218A (en) * | 2020-10-26 | 2021-02-05 | 西北大学 | Zwitterionic polymer and heparin composite coating, preparation method and application thereof |
| CN112375191A (en) * | 2020-10-30 | 2021-02-19 | 清华大学 | Block copolymer, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 钱涛: "磷铵类两性离子修饰的新型抗凝血材料的合成与性质研究", 《中国优秀硕士学位论文全文数据 医药卫生科技辑》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114081674A (en) * | 2021-09-28 | 2022-02-25 | 四川大学华西医院 | Valve leaflet segmenting device |
| CN114081674B (en) * | 2021-09-28 | 2023-08-15 | 四川大学华西医院 | Valve leaf segmentation device |
| CN113769169A (en) * | 2021-10-22 | 2021-12-10 | 四川大学华西医院 | Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof |
| WO2023088330A1 (en) * | 2021-11-17 | 2023-05-25 | 四川大学 | Biological valve material, and preparation method therefor and use thereof |
| CN114984332A (en) * | 2022-05-27 | 2022-09-02 | 山东大学 | Dopamine-heparin composite anticoagulant coating and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113101412A (en) | Long-acting stable anticoagulation biological valve material and preparation method thereof | |
| US20160375180A1 (en) | Method for producing medical device and medical device | |
| US20230093191A1 (en) | Biological Material And Preparation Method Therefor | |
| WO2021239080A1 (en) | Biological heart valve with both anticoagulation and anti-calcification properties, and preparation method therefor | |
| CN112220971B (en) | Artificial biological heart valve and preparation method thereof | |
| CN106474568B (en) | Surface-modified metal and method for modifying metal surface | |
| CN111420120A (en) | Biological valve with anticoagulation and anti-calcification functions and preparation method thereof | |
| CN113713183A (en) | Biomedical coating with excellent long-acting anticoagulation, antibiosis and anti-fouling performances and preparation method thereof | |
| WO2023216874A1 (en) | Surface grafted cross-linked zwitterionic polymer coating, preparation method therefor, and use thereof | |
| CN114748696B (en) | Double-bond cross-linked biological valve material after co-cross-linking, and preparation method and application thereof | |
| CN113082292A (en) | Biological valve material modified by zwitterionic polymer and preparation method thereof | |
| JP6195335B2 (en) | Polymer compound, composition using the same, and medical device | |
| CN110669168B (en) | Modifying agent, preparation method and use method thereof and medical material | |
| WO2020181857A1 (en) | Medical tube and preparation method therefor | |
| JP2008264266A (en) | Treatment liquid of medical material and medical material | |
| WO2022212812A1 (en) | Zwitterionic triple-network hydrogel compositions and methods of use | |
| EP2992909B1 (en) | Metal medical device | |
| US7175979B2 (en) | Preserved tissue matrix of a hollow organ, particularly of a blood vessel, a method of producing same, and the use thereof | |
| JP2012040101A (en) | Support body having ph-responsive polymer | |
| WO2023088330A1 (en) | Biological valve material, and preparation method therefor and use thereof | |
| CN115970060B (en) | Method for improving calcification resistance and anticoagulation performance of biological valve material by double bond post-crosslinking | |
| CN210873229U (en) | Catheter for resisting adhesion of protein and extracellular matrix | |
| JPH11226113A (en) | Blood compatible polyurethane-hydrophilic high polymer blend | |
| CN115887770A (en) | Biological valve material crosslinked by utilizing isocyano ethyl methacrylate, medical instrument, method and application thereof | |
| JPH09103481A (en) | Medical treatment implement having surface excellent in bioadaptability and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210713 |